Showing 1 - 20 results of 2,561 for search '(( a small decrease ) OR ((( _ ((teer decrease) OR (nn decrease)) ) OR ( _ largest decrease ))))', query time: 0.51s Refine Results
  1. 1
  2. 2
  3. 3

    Data and code from: Continental declines in North American small mammal populations by Alec Medd (20968740)

    Published 2025
    “…The resulting database is the largest collection of multi-year abundance data for North American small mammals. …”
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. by Charlotte J. van Ginkel (20790466)

    Published 2025
    “…PS decreased TEER. (C) Different treatments (treatment groups n = 8)with HA and/or CS did not affect TEER recovery after PS treatment, full recovery was seen in all groups after 24 hours. …”
  11. 11
  12. 12

    BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Changes in TEER with increasing culture time on days 1–22. (<b>B)</b> BA alleviated the LPS-induced decrease in TEER in Caco2 cells after treatment for 24 h. …”
  13. 13
  14. 14

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”